MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma.
Paul G. Richardson
Consultant or Advisory Role - Celgene; Johnson & Johnson; Millennium
Craig Hofmeister
Consultant or Advisory Role - Celgene
Research Funding - Celgene; Millennium
Noopur S. Raje
Consultant or Advisory Role - Celgene
David Samuel DiCapua Siegel
Consultant or Advisory Role - Celgene; Merck; Millennium; Onyx
Honoraria - Celgene; Merck; Millennium; Onyx
Sagar Lonial
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Millennium; Novartis
Jacob Laubach
Research Funding - Novartis; Onyx
Yvonne Adeduni Efebera
No relevant relationships to disclose
David H. Vesole
Consultant or Advisory Role - Celgene
Honoraria - Celgene; Millennium
Ajay K. Nooka
No relevant relationships to disclose
Jacalyn Rosenblatt
No relevant relationships to disclose
Mohamed H. Zaki
Employment or Leadership Position - Celgene
Ye Hua
Employment or Leadership Position - Celgene
Yan Li
Employment or Leadership Position - Celgene
Sheetal Shah
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Jianming Wang
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Kenneth Carl Anderson
Consultant or Advisory Role - Celgene; Millennium